Ronald Brazg

5.3k total citations · 1 hit paper
44 papers, 3.0k citations indexed

About

Ronald Brazg is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Ronald Brazg has authored 44 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Surgery and 13 papers in Genetics. Recurrent topics in Ronald Brazg's work include Diabetes Management and Research (34 papers), Pancreatic function and diabetes (21 papers) and Hyperglycemia and glycemic control in critically ill and hospitalized patients (16 papers). Ronald Brazg is often cited by papers focused on Diabetes Management and Research (34 papers), Pancreatic function and diabetes (21 papers) and Hyperglycemia and glycemic control in critically ill and hospitalized patients (16 papers). Ronald Brazg collaborates with scholars based in United States, Israel and Ireland. Ronald Brazg's co-authors include Ronald M. Krauss, Diane L. Tribble, Alan Chait, Timothy S. Bailey, Kaifeng Lu, Julio Rosenstock, Peter Stein, Richard L. Weinstein, Sherwyn Schwartz and Satish K. Garg and has published in prestigious journals such as Diabetes Care, Diabetes and The American Journal of Medicine.

In The Last Decade

Ronald Brazg

43 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes

2017 415 citations Satish K. Garg, Bruce A. Buckingham et al. Diabetes Technology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ronald Brazg United States	23	2.4k	1.6k	870	419	217	44	3.0k
N. Jeandidier France	27	1.4k 0.6×	893 0.6×	534 0.6×	322 0.8×	118 0.5×	95	2.1k
Cornelia Haug Germany	26	1.4k 0.6×	684 0.4×	457 0.5×	271 0.6×	272 1.3×	105	2.1k
Julia K. Mader Austria	28	1.7k 0.7×	1.0k 0.6×	832 1.0×	224 0.5×	141 0.6×	165	2.5k
Christoph Kapitza Germany	30	2.6k 1.1×	1.4k 0.9×	480 0.6×	906 2.2×	88 0.4×	76	3.2k
Jeremy Pettus United States	28	2.2k 0.9×	1.5k 0.9×	1.1k 1.3×	385 0.9×	75 0.3×	74	2.9k
Massimo Massi‐Benedetti Italy	23	2.4k 1.0×	1.2k 0.8×	713 0.8×	679 1.6×	73 0.3×	55	3.1k
Martin Ellmerer Austria	26	1.2k 0.5×	631 0.4×	387 0.4×	398 0.9×	297 1.4×	71	2.3k
Elena Toschi United States	29	2.8k 1.2×	2.0k 1.2×	1.6k 1.9×	897 2.1×	58 0.3×	74	4.0k
Stefano Genovese Italy	37	2.4k 1.0×	1.6k 1.0×	1.3k 1.5×	1.1k 2.5×	55 0.3×	126	4.3k
Leszek Nosek Germany	28	2.8k 1.2×	1.7k 1.1×	859 1.0×	452 1.1×	70 0.3×	58	3.3k

Countries citing papers authored by Ronald Brazg

Since Specialization

Citations

This map shows the geographic impact of Ronald Brazg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Brazg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Brazg more than expected).

Fields of papers citing papers by Ronald Brazg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Brazg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Brazg. The network helps show where Ronald Brazg may publish in the future.

Co-authorship network of co-authors of Ronald Brazg

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Brazg. A scholar is included among the top collaborators of Ronald Brazg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Brazg. Ronald Brazg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bailey, Timothy S., David R. Liljenquist, Douglas Denham, et al.. (2025). Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics. 27(5). 407–411. 2 indexed citations

Alva, Shridhara, Ronald Brazg, Kristin Castorino, et al.. (2023). Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System. Diabetes Therapy. 14(4). 767–776. 40 indexed citations

Garg, Satish K., David R. Liljenquist, Bruce W. Bode, et al.. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics. 24(2). 84–92. 51 indexed citations

Christiansen, Mark P., et al.. (2020). Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies. Diabetes Technology & Therapeutics. 23(3). 187–194. 5 indexed citations

Grosman, Benyamin, Anirban Roy, Di Wu, et al.. (2020). 1006-P: Personalized Hybrid Closed-Loop Therapy Using a Digital Twin in Patients with Type 1 Diabetes: At-Home Data. Diabetes. 69(Supplement_1). 4 indexed citations

Bailey, Timothy S., Ronald Brazg, Erwin S. Budiman, et al.. (2019). 910-P: Improved Accuracy of 14-Day Factory-Calibrated FreeStyle Libre System with New Glucose Algorithm. Diabetes. 68(Supplement_1). 10 indexed citations

Klonoff, David C., Joan Lee Parkes, Boris Kovatchev, et al.. (2018). Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. Diabetes Care. 41(8). 1681–1688. 101 indexed citations

Bailey, Timothy S., Andrew Ahmann, Ronald Brazg, et al.. (2014). Accuracy and Acceptability of the 6-Day Enlite Continuous Subcutaneous Glucose Sensor. Diabetes Technology & Therapeutics. 16(5). 277–283. 71 indexed citations

Garg, Satish K., Ronald Brazg, Timothy S. Bailey, et al.. (2014). Hypoglycemia Begets Hypoglycemia: The Order Effect in the ASPIRE In-Clinic Study. Diabetes Technology & Therapeutics. 16(3). 125–130. 14 indexed citations

10.

Brazg, Ronald, John G. Toffaletti, Elizabeth Johnston Taylor, et al.. (2013). Clinical evaluation of the FreeStyle Precision Pro system. Clinica Chimica Acta. 421. 243–250. 11 indexed citations

11.

Garg, Satish K., Ronald Brazg, Timothy S. Bailey, et al.. (2012). Reduction in Duration of Hypoglycemia by Automatic Suspension of Insulin Delivery: The In-Clinic ASPIRE Study. Diabetes Technology & Therapeutics. 14(3). 205–209. 101 indexed citations

12.

Keenan, D. Barry, John J. Mastrototaro, Howard Zisser, et al.. (2011). Accuracy of the Enlite 6-Day Glucose Sensor with Guardian and Veo Calibration Algorithms. Diabetes Technology & Therapeutics. 14(3). 225–231. 77 indexed citations

13.

Brazg, Ronald, Timothy S. Bailey, Satish K. Garg, et al.. (2011). The ASPIRE Study: Design and Methods of an In-Clinic Crossover Trial on the Efficacy of Automatic Insulin Pump Suspension in Exercise-Induced Hypoglycemia. Journal of Diabetes Science and Technology. 5(6). 1466–1471. 18 indexed citations

14.

Brazg, Ronald, Lei Xu, Chiara Dalla Man, et al.. (2006). Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 9(2). 186–193. 123 indexed citations

15.

Rosenstock, Julio, et al.. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics. 28(10). 1556–1568. 434 indexed citations

16.

Hunninghake, Donald B., Mark E. McGovern, Michael J. Koren, et al.. (2003). A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology. 26(3). 112–118. 45 indexed citations

17.

Isaacsohn, Jonathan L., William Insull, Evan A. Stein, et al.. (2001). Long-Term Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Primary Hypercholesterolemia. Clinical Cardiology. 24(S4). 1–9. 12 indexed citations

18.

Brazg, Ronald & E L Bierman. (1993). Insulin excess counteracts the effects of HDL on intracellular sterol accumulation in cultured human skin fibroblasts. Diabetologia. 36(10). 942–947. 8 indexed citations

19.

Chait, Alan, Ronald Brazg, Diane L. Tribble, & Ronald M. Krauss. (1993). Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. The American Journal of Medicine. 94(4). 350–356. 449 indexed citations

20.

Zambon, Sabina, et al.. (1992). The effect of probucol on HDL-mediated sterol translocation and efflux from cells. Atherosclerosis. 94(1). 51–60. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact